Cho-hung Chiang
TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.
Journal: Diabetes, obesity & metabolism
Published: May 10, 2026
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
Journal: Annals of internal medicine
Published: December 08, 2025
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.
Journal: Journal of thrombosis and haemostasis : JTH
Published: May 07, 2025
Cardiovascular and thromboembolic outcomes with immune checkpoint inhibitors in gastroesophageal cancer: a propensity score-matched cohort study.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: November 06, 2024
Cytotoxic T-lymphocyte associated protein 4 inhibitors are associated with a higher risk of cardiovascular events than programmed cell death protein 1 inhibitors in patients with melanoma.
Journal: Journal of the American Academy of Dermatology
Published: October 30, 2024
Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists.
Journal: European journal of preventive cardiology
Published: September 04, 2024
Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 20, 2024
Last Updated: 09/26/2026